BLCM Stock Overview
Bellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Bellicum Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.075 |
| 52 Week High | US$1.31 |
| 52 Week Low | US$0.06 |
| Beta | 1.38 |
| 1 Month Change | -6.68% |
| 3 Month Change | -66.74% |
| 1 Year Change | -91.58% |
| 3 Year Change | -98.16% |
| 5 Year Change | -99.77% |
| Change since IPO | -99.97% |
Recent News & Updates
Shareholder Returns
| BLCM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -18.2% | 0.4% | 1.0% |
| 1Y | -91.6% | 0.9% | 21.9% |
Return vs Industry: BLCM underperformed the US Biotechs industry which returned 10.6% over the past year.
Return vs Market: BLCM underperformed the US Market which returned 24.4% over the past year.
Price Volatility
| BLCM volatility | |
|---|---|
| BLCM Average Weekly Movement | 23.6% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BLCM's share price has been volatile over the past 3 months.
Volatility Over Time: BLCM's weekly volatility has decreased from 41% to 24% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 13 | Dave Maggio | www.bellicum.com |
Bellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company’s clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen.
Bellicum Pharmaceuticals, Inc. Fundamentals Summary
| BLCM fundamental statistics | |
|---|---|
| Market cap | US$879.47k |
| Earnings (TTM) | -US$22.38m |
| Revenue (TTM) | US$1.51m |
0.6x
P/S Ratio0.0x
P/E RatioIs BLCM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BLCM income statement (TTM) | |
|---|---|
| Revenue | US$1.51m |
| Cost of Revenue | US$18.63m |
| Gross Profit | -US$17.12m |
| Other Expenses | US$5.26m |
| Earnings | -US$22.38m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.90 |
| Gross Margin | -1,135.08% |
| Net Profit Margin | -1,483.95% |
| Debt/Equity Ratio | 0% |
How did BLCM perform over the long term?
See historical performance and comparison